Aliases:This biomarker is also known as:
- NuMA binding protein 1,
- NuMA-binding protein 1,
- Glioma-amplified sequence 41,
- YEATS domain containing 4,
- glioma-amplified sequence 41,
- YEATS domain-containing protein 4,
- nuMA-binding protein 1,
- glioma-amplified sequence-41,
YEATS4 has high sequence similarity to human MLLT1, and yeast and human MLLT3 proteins, both transcription factors, and is therefore hypothesized to be a transcription factor itself. YEATS4 is thought to be required for RNA transcription. YEATS4 is also a component of the NuA4 histone acetyltransferase (HAT) complex.
There are no datasets associated with this biomarker.
The following organs have data associated with this biomarker…
|QA State:||Under Review|
No additional breast data available.
YEATS4 was one of numerous potential early detection biomarkers specific to triple-negative breast cancer in multiple pathways identified.
- Discovery and preliminary confirmation of novel early detection biomarkers for triple-negative breast cancer using preclinical plasma samples from the Women's Health Initiative observational study.
- Development and validation of sandwich ELISA microarrays with minimal assay interference.
- Plasma biomarker profiles differ depending on breast cancer subtype but RANTES is consistently increased.